Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report [PDF]
Polycythemia vera is a chronic progressive myeloproliferative disease characterized by increased circulating red blood cells, and the hyperviscosity of the blood can lead to an increased risk of arterial thrombosis.
Hyeongwoo Im +4 more
doaj +1 more source
Aberrant expression of microRNA in polycythemia vera
Background Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis.
Hana Bruchova +2 more
doaj +1 more source
Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
TET2 mutations are found in polycythemia vera and it was initially reported that there is a greater TET2 mutational burden than JAK2V617F in polycythemia vera stem cells and that TET2 mutations precede JAK2V617F.
Sabina I. Swierczek +7 more
doaj +1 more source
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon +8 more
doaj +1 more source
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V. +8 more
core +1 more source
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey +5 more
doaj +1 more source
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo +41 more
core +5 more sources
Hereditary hemochromatosis and JAK2‐positive polycythemia vera
A 59‐year‐old man was diagnosed with JAK2‐positive polycythemia vera. Subsequently, further laboratory testing revealed elevated ferritin and iron saturation.
Ahmed Radwan, Ibraheem Othman
doaj +1 more source
Macrophages support pathological erythropoiesis in Polycythemia Vera and Beta-Thalassemia [PDF]
Regulation of erythropoiesis is achieved by integration of distinct signals. Among these, macrophages are emerging as erythropoietin-complementary regulators of erythroid development, particularly under stress conditions. We investigated the contribution
Abdel-Wahab, Omar +15 more
core +1 more source
Double Thrombosis- Interesting Case of Polycythemia Vera [PDF]
Polycythemia vera is a myeloproliferative disorder which has a varied manifestation, one of it being venous thrombosis and arterial thrombosis which significantly contributes to the mortality and morbidity.
Subashini Subramanian +1 more
doaj +1 more source

